Can LDL cholesterol be too low?

In FOURIER, 10% of the 25,982 patients analyzed reached LDL-C below 19 mg/dL (0.5 mmol/L)0.5 mmol/L (19 mg/dL) after four weeks, nearly all of them on evolocumab. Cardiovascular risk fell steadily all the way down to the bottom percentile, below 0.2 mmol/L, and none of ten prespecified safety events rose [1].

In the open-label extension, 24% of 6,559 patients averaged below 20 mg/dL. They had the fewest events, and there was no link between lower LDL and serious adverse events, cancer, cataracts, hemorrhagic stroke, new diabetes, neurocognitive events or muscle problems [2].

Pooled statin trials found no rise in cancer, even at low LDL-C [5].

Cells build cholesterol from scratch and only take up LDL through receptors when they need more [6].

Nature ran its own trial. People born with PCSK9 variants have lower LDL-C for life, and in one cohort a 28% lower level came with 88% fewer coronary events and no reported downside [7].

In a cognitive trial of 1,204 patients, evolocumab did not change memory, executive function or psychomotor speed over 19 months, and there was no link between LDL level and cognitive change [3].

Both the European and the 2026 US guidelines set below 55 mg/dL (1.4 mmol/L)1.4 mmol/L (55 mg/dL) as the goal at very high risk [8] [9]. Neither sets a floor below which treatment should be reduced.

Trial targets sit lower still. FOURIER lowered LDL-C from a median 92 to 30 mg/dL (2.4 to 0.78 mmol/L)2.4 to 0.78 mmol/L (92 to 30 mg/dL) on top of statins [10]. ODYSSEY OUTCOMES adjusted the alirocumab dose to aim for 25 to 50 mg/dL (0.6 to 1.3 mmol/L)0.6 to 1.3 mmol/L (25 to 50 mg/dL) and cut recurrent events by 15% [11].

Genetic data suggest that lifelong exposure counts: each 38.7 mg/dL (1 mmol/L)1 mmol/L (38.7 mg/dL) of genetically lower LDL-C meant 54.5% lower coronary risk [12]. That is one reason some physicians argue for lower levels earlier in life, a view that goes beyond current guidelines.

Genetic variants that mimic statins raise body weight and diabetes risk slightly, which suggests the diabetes effect comes at least partly from blocking the statin target itself [4]. In FOURIER-OLE, very low LDL-C on evolocumab was not linked to new diabetes [2].

In CLEAR Outcomes, gout occurred in 3.1% on bempedoic acid versus 2.1% on placebo, and gallstones in 2.2% versus 1.2% [13]. PCSK9 antibodies caused more injection-site reactions, 2.1% versus 1.6% [10].

These effects are weighed against the cardiovascular benefit, which grows with your baseline risk. Your clinician can help you weigh them.

In a Danish cohort of 108,243 people, all-cause mortality was 25% higher at LDL-C below 70 mg/dL (1.8 mmol/L)1.8 mmol/L (70 mg/dL) than at 132 to 154 mg/dL, even though any rise in LDL-C was linked to more heart attacks [14]. Observational data cannot show whether low LDL caused those deaths. Many illnesses lower cholesterol, so a low value can be a marker of disease rather than a cause.

That is why an unexpected fall in LDL deserves a look at the bigger picture, including thyroid function and overall health, rather than reassurance alone.

In nearly 5 million lipid panels with triglycerides of 200 to 399 mg/dL and LDL-C below 70 mg/dL, Friedewald underestimated LDL-C in 60% of patients, Sampson-NIH in 39% and Martin-Hopkins in 17% [15]. An underestimate can make LDL look lower than it is.

If your report shows a low calculated LDL with high triglycerides, ask about a direct LDL, the Martin-Hopkins method or apoB. See how LDL is measured.